tbuckley/cabot-search huggingface dataset:
FRI0339 Development of a Novel Patient Reported Outcome (PRO) Measure: The Systemic Lupus Erythematosus (SLE) Steroid Questionnaire (SSQ):
Authors: S.D. Mathias, P. Berry, J. deVries, A. Askanase, K. Pascoe, H. Colwell, D. Chang
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Many SLE patients receive oral glucocorticoids (steroids) as part of their treatment regimen. While providing symptom relief, most patients experience short- and long-term side effects associated with steroid use. <h3>Objectives</h3> To develop a PRO to assess benefits, side effects, and impact associated with steroid use in SLE patients. <h3>Methods</h3> Following IRB approval, 6 US rheumatology practices enrolled SLE patients with current or recent (past year) steroid use to participate in concept elicitation (CE) interviews about their steroid experience. A draft SSQ was developed, cognitively debriefed (CD) with SLE subjects, and finalized based on patient feedback, clinical input and a translatability assessment (an evaluation to assure words can be easily translated into other languages). <h3>Results</h3> 33 subjects (95% female, 55% Caucasian, 25% African American, mean age 47 years, 52% moderate/severe SLE) completed CE interviews. Subjects reported symptom improvement and increased energy. Common side effects included weight gain (67%), swelling/moon face (36%), and mood swings/feelings of rage (21%). Most subjects (67%) would be happier if steroids were discontinued. During CD interviews (n=13), the SSQ was found to be comprehensive, clear, and relevant. Minor revisions were made to improve clarity. Key results from CE interviews and a summary of the final SSQ content are provided below. <h3>Conclusions</h3> The SSQ is the first comprehensive PRO, developed with significant patient and clinical input, to assess SLE patient experience of oral steroid use. Its measurement properties will be evaluated in the future. <h3>Acknowledgements</h3> The research presented in this abstract was funded by GlaxoSmithKline, USA. <h3>Disclosure of Interest</h3> S. D. Mathias Consultant for: GlaxoSmithKline, P. Berry Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, J. deVries Shareholder of: GlaxoSmithKline, A. Askanase Consultant for: GlaxoSmithKline, K. Pascoe Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, H. Colwell Consultant for: GlaxoSmithKline, D. Chang Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline
Being fit throughout life brings benefits in older age, study finds
Authors: Jacqui Wise
Journal: BMJ (2016)

Being fitter in midlife is associated with a lower risk of stroke after age 65, independent of traditional risk factors such as high blood pressure and type 2 diabetes, says a new study published in the American Heart Association’s journal Stroke .1

The researchers used data from the Cooper Center Longitudinal Study, which included 19 815 Medicare patients in Dallas, Texas, who were followed …
Impact of mindfulness training on avoidant coping and advance care planning.
Authors: Shelley A. Johns, Kathleen Beck-Coon, Karen Schmidt, Timothy E. Stump, Jennifer Kim Bernat, Alexia M. Torke, Paul R. Helft
Journal: Journal of Clinical Oncology (2014)

86 Background: Timely end-of-life (EOL) discussions and advance care planning (ACP) are crucial to quality cancer care; however, patients, family caregivers (CGs), and oncologists often avoid these tender conversations. When EOL discussions are avoided, patients are more likely to receive non-beneficial treatment near death and CGs are more likely to experience psychiatric disturbance. Mindfulness meditation facilitates emotional regulation and may enhance adaptive coping necessary for EOL discussions and ACP. Methods: Mindfully Optimizing Delivery of End-of-Life (MODEL) Care is a within-group pilot study developed to train patients with advanced-stage solid malignancies and their CGs (n=13 dyads) in present-moment awareness and non-reactive coping through a variety of mindfulness practices. Eligible patients met a threshold for avoidant coping and had not completed a Physician Orders for Scope of Treatment (POST) form documenting care preferences. Cognitive avoidance and quality of life (QoL) for patients and CGs were assessed from baseline (T1) to post-intervention (T2) and 1-month follow-up (T3) with standardized response mean (SRM) effect sizes. ACP from T1 to T3 was assessed descriptively. Results: Moderate decreases in cancer-related avoidance were found for patients (SRM=-0.47) and CGs (SRM=-0.59) T1 to T2, while T1 to T3 effects were small for patients (SRM=-0.31) and large for CGs (SRM=-1.12). At T1, no patient had completed a POST form; by T3, 50% reported completing one and 40% were preparing to do so soon. At T1, 23% of patients reported having had a ‘goals of care’ discussion with their oncologist, with 82% doing so by T3. At T1, 46% of patients reported having discussed ‘goals of care’ with their CGs, with 100% doing so by T3. Large improvements in QoL were found at both time points for patients and CGs (SRMs ranging from 0.85 to 1.21). Conclusions: Mindfulness was associated with mostly moderate reductions in avoidant coping and large improvements in QoL for patients and caregivers, with notable ACP progress for patients.
Relations among clinical scales in schizophrenia
Authors: R E Gur, P D Mozley, S M Resnick, S Levick, R Erwin, A J Saykin, R C Gur
Journal: American Journal of Psychiatry (1991)

Clinical scales have become established as tools to quantify phenomenological features of schizophrenia. The goal of this study was to examine relations among the following: the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms, the Scale for the Assessment of Negative Symptoms, and the deficit-nondeficit classification.Forty-seven patients with schizophrenia were recruited according to specific inclusion and exclusion criteria. The standardized assessment procedures were administered by a trained psychiatric research team.Examination of the BPRS showed that the patients had highest scores on the thought disorder factor and the symptoms specific to schizophrenia. Classification of patients as having the positive, negative, or mixed type of schizophrenia resulted in a finding of seven with the positive, seven with the negative, and 33 with the mixed type. The division of patients into those with the deficit syndrome (N = 29) and those without (N = 18) was related to symptom specificity and to positive and negative symptoms. Deficit syndrome patients had more symptoms specific to schizophrenia, fewer nonspecific symptoms, and, as expected, greater severity of negative symptoms. Cluster analysis revealed three clusters of patients: those with low negative symptom scores and high scores on specific symptoms (the majority were without the deficit syndrome); those with high scores on negative, positive, and specific symptoms (the majority had the deficit syndrome); and those with lower scores on specific symptoms and high scores on negative and positive symptoms (the majority had the deficit syndrome).The scales showed some overlap but also seemed to measure complementary aspects of the phenomenology of schizophrenia. Subtypes of patients identified by the combined use of these scales may differ in underlying pathology.
Augmentation of Hematoporphyrin Uptake and in Vitro-Growth Inhibition of L1210 Leukemia Cells by Succinylacetone
Authors: P S Ebert, R A Hess, D P Tschudy
Journal: JNCI Journal of the National Cancer Institute (1985)

Succinylacetone (SA; 4,6-dioxoheptanoic acid), a specific inhibitor of δ-aminolevulinic acid dehydrase (ALAD) (the second enzyme of the heme biosynthetic pathway), was tested for its effect in L1210 cells from inbred DBA/2 mice. ALAD from broken L1210 cells was completely inhibited by 1 µM SA, but in whole cells activity was decreased only 83% after incubation of the cells with 2.5 mM SA for 3 days. When incubated with hematoporphyrin (HP), L1210 cells rapidly took up porphyrin from the medium, and this uptake could be augmented by pretreatment of the cells with SA; but this enhancement of porphyrin uptake occurred gradually over a period of days. When SA-treated and untreated L1210 cells were incubated with increasing concentrations of HP in the medium, SA-treated cells reached the saturation concentration of cellular porphyrin at lower medium HP concentrations than did untreated cells. Growth of L1210 cells could be inhibited by 2 mM SA or more. Addition of increasing amounts of serum to cultures of cells containing SA did not reverse the growth inhibition due to SA. Porphyrin uptake from HP in the medium in nonmalignant fibroblast line 3T3 was much lower than in L1210 cells and could not be enhanced by incubation of the cells with SA.
The <italic>In Vitro</italic> Initiation of Pulmonary Adenomas in Fetal Mouse Lung by a Single Exposure to Ultraviolet Irradiation of Wavelength 2,537 Å<xref ref-type="fn" rid="fn1">2</xref>
Authors: Stanfield Rogers
Journal: JNCI Journal of the National Cancer Institute (1955)

The In Vitro Initiation of Pulmonary Adenomas in Fetal Mouse Lung by a Single Exposure to Ultraviolet Irradiation of Wavelength 2,537 Å Stanfield Rogers Stanfield Rogers Department of Pathology, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 4, February 1955, Pages 1001–1004, https://doi.org/10.1093/jnci/15.4.1001 Published: 01 February 1955 Article history Received: 29 September 1954 Published: 01 February 1955
Pneumatic Dilation in Achalasia
Authors: N.  Vakil, S.  Kadakia, V.  F.  Eckardt
Journal: Endoscopy (2003)

Achalasia is a primary disorder of esophageal motor function, of unknown etiology, that is characterized by insufficient or absent lower esophageal sphincter (LES) relaxation and loss of peristalsis in the esophagus. These abnormalities are recognized radiographically by aperistalsis, esophageal dilation, and decreased opening of the LES, with a characteristic “bird-beak” appearance. The principal symptom of this disorder is dysphagia and pneumatic dilation is designed to alleviate or cure this symptom.
AB0343 Thyroid Autoantibodies in Seropositive Versus Seronegative Rheumatoid Arthritis: Is There a Link?
Authors: E. Soliman, K. Ghitany, M. Bondok, S. Elmaadawy
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid arthritis (RA) and autoimmune thyroid disease (AITD) tend to cluster together. However the relation between RA autoantibodies and thyroid autoantibodies is debatable. <h3>Objectives</h3> To investigate the relation between RA autoantibodies namely anti-cyclic citrullinated peptide (anti –CCP) and rheumatoid factor (RF) and autoimmune thyroid markers [thyroid peroxidase antibodies (anti-TPO), thyroglobulin antibodies (anti-TG) and TSH receptor antibodies (TRAbs)] in RA patients. <h3>Methods</h3> The study included 70 RA patients, subclassified according to the presence of RF and anti-CCP into 35 seropositive RA patients (positive to one or both seromarkers), and 35 seronegative RA (negative to both seromarkers). 20 healthy age and sex matched were also included as controls. Detailed history and physical examination focusing on clinical features suggestive of thyroid dysfunction and disease activity score (DAS 28) were assessed. Investigations included measurement of thyroid stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxin (TT4), anti-TPO, anti-TG, and TRAbs in addition to ESR and CRP. Ultrasound neck for assessing thyroid was done in all patients and controls. <h3>Results</h3> Hypothyroidism was found in 20/70 (28.57%) RA compared to 15% of controls. Whereas hyperthyroidism was found in 4/70 RA patients (5.71%) compared to 0% of controls. There was no significant difference in thyroid dysfunction between seropositive and negative patients. Mean levels of anti-TPO, anti-TG and TRAbs were significantly higher in RA patients versus controls (p&lt;0. 001). Furthermore, mean anti-TPO was significantly higher in seropositive than seronegative RA (1301. 9±1716. 0 and 799. 4±1597. 7 respectively) (P&lt;0.001). Anti-TG was higher in seropositive than seronegative RA (1750. 0±1866.2 and 898. 1±988. 11 respectively) (P&lt;0.001). Similarly, TRAbs were significantly higher in seropositive than negative RA (p=0. 006). Ultrasonographic thyroiditis was significantly evident in RA patients versus control (p=0.001) with no difference between seropositive and negative RA. Significant positive correlation was found between RA autoantibodies (RF and anti-CCP) and thyroid autoantibodies in seropositive patients. <h3>Conclusions</h3> Thyroid dysfunction and AITD are common in RA patients, with hypothyroidism being the commonest regardless of RA serostatus and disease activity assessed by DAS 28. Seropositivity to RF and/ or anti-CCP infers a state of increased immune reactivity in RA as evidenced by the significantly higher levels of all thyroid autoantibodies in seropositive patients than seronegatives and controls and by the positive correlation between the RA autoantibodies and thyroid autoantibodies. Accordingly, screening for thyroid autoantibodies in RA patients especially seropositives is recommended. <h3>Disclosure of Interest</h3> None declared
P94 c-Rel AND p27Kip ARE DOWNSTREAM TARGETS OF ERK5 IN HEPATOCELLULAR CARCINOMA (HCC) IN VIVO AND IN VITRO
Authors: G. Di Maira, E. Rovida, N. Navari, S. Cannito, P. Della Sbarba, M. Parola, F. Marra
Journal: Journal of Hepatology (2014)
Qualitative Comparison of the Growth of Chick-Heart and Strain L Fibroblasts Planted as Suspensions on Pyrex Glass and Perforated Cellophane Substrates&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: John E. Shannon, Jr., Wilton R. Earle
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Qualitative Comparison of the Growth of Chick-Heart and Strain L Fibroblasts Planted as Suspensions on Pyrex Glass and Perforated Cellophane Substrates Get access John E. Shannon, Jr., John E. Shannon, Jr. National Cancer Institute4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Wilton R. Earle Wilton R. Earle National Cancer Institute4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 1, August 1951, Pages 155–177, https://doi.org/10.1093/jnci/12.1.155 Published: 01 August 1951 Article history Received: 18 April 1951 Published: 01 August 1951
Case 9-1969
Authors: William H. Baker, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of Case First admission. A fifty-six-year-old woman was admitted to the hospital because of fever.She had been well until a month previously, when there was the onset of daily chills and sweats, with elevation of the temperature to between 102 and 104°F. She had had no cough, pain in the chest or abdomen, dysuria or urinary frequency. She had been taking exercises for stiffness of the thigh muscles but had experienced no articular discomfort. On physical examination in another hospital there were no abnormal physical findings. Urinalysis was negative; the hematocrit was 37 per cent, and the . . .
Cross-reactivity of antibodies to viruses belonging to the Semliki forest serocomplex
Authors: R J Hassing, I Leparc-Goffart, H Tolou, G van Doornum, P J van Genderen
Journal: Eurosurveillance (2010)

Preview this article: Cross-reactivity of antibodies to viruses belonging to the Semliki forest serocomplex, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/23/art19588-en-1.gif
Health promotion in general practice
Authors: P. Pharoah, S. Sanderson
Journal: BMJ (1994)

Health promotion in general practiceRefine the approach-don't abandon the principle EDrrOR,-The problem with interpreting both the Family Heart Study Group's report of its one year trial' and the result of the less interventionist OXCHECK study2 is that both studies tripped at the second hurdle for any clinical trial: after randomisation they failed to "screen" their controls in exactly the same way as they screened the intervention group.The Family Heart Study
“Chimera” fully covered self-expandable metal stent for refractory esophageal anastomotic leak
Authors: Massimiliano Mutignani, Lorenzo Dioscoridi, Raffaele Manta, Edoardo Forti, Francesco Pugliese, Domenico D’Ugo, Roberto Persiani
Journal: Endoscopy (2015)

Self-expandable stents are used to treat postoperative leaks and fistulas in the upper gastrointestinal tract [1] [2] [3]. However, a discrepancy between stent size and lumen size may lead to insufficient sealing of a leak, requiring further surgical intervention [4] [5]. The main reason why this problem occurs is the relatively small diameter of commonly used commercial stents [5].
Cresyl Violet as a Fluorophore in Confocal Laser Scanning Microscopy for Future In-Vivo Histopathology
Authors: M George, A Meining
Journal: Endoscopy (2003)

Background and Study Aims: Confocal laser scanning microscopy appears to be a key technology for future endoluminal diagnostic tools for obtaining noninvasive optical biopsies. Until now, clinical use of this technique has been problematic, as successfully tested dyes are toxic. In the present study, cresyl violet acetate was evaluated as a nontoxic staining agent for in-vivo histopathology. Materials and Methods: Esophageal and gastric mucosa from the swine was obtained and examined ex vivo with a commercially available confocal laser scanning microscope. A series of images was recorded for concentrations of cresyl violet ranging from 0.1 % to 10 % for both esophageal and gastric mucosa. Staining was carried out for 2 min after mucolysis with acetylcysteine. Results: Staining with 2 % cresyl violet led to identification of nuclei and cell membranes. Lower concentrations were associated with a lack of homogeneous dye absorption in particular in the gastric mucosa. Conclusions: Cresyl violet is a clinically usable fluorophore for confocal laser scanning microscopy. Its use in combination with an endoluminally applicable system has the potential to allow in vivo histopathology.
Neoplastic pulmonary lymphangitis: Symptomatic treatment and quality-of-life evaluation in a prospective palliative care series
Authors: A. A. Dettino, T. Pagano, C. Jardim, T. Takagaki, D. Deheinzelin, V. N. Okamoto, I. Bensenor, A. L. Teodoro, S. C. Serrano, E. M. Negri
Journal: Journal of Clinical Oncology (2007)

19536 Background: Neoplastic lymphangitis, or lymphangitis carcinomatosa, is a rare and distressing form of lung metastasis, for which symptom improvement is strongly necessary. Since measuring quality of life is an important step toward improving symptom management in cancer patients, and dyspnea in pulmonary lymphangitis is a complex syndrome in end-of-life care, we focused on evaluating a cohort of those individuals. Methods: 52 consecutive patients with neoplastic pulmonary lymphangitis (NPL) were prospectivelly followed in 3 services, with quality of life (QoL) evaluation also, using Medical Outcomes Study 36-item Short-Form Health Survey (SF- 36) and Saint George's Respiratory Questionnaire (SGRQ). Results: 65% (34) of patients were female; age ranged from 37 to 84 years (median: 60). Primary tumor sites were: 28 lung (54%), 18 breast (35%), 5 digestive (9%) and 1 bone cancer. Histological findings were of adenocarcinoma in most cases (71%). Karnofsky performance scale ranged from 10 to 90% (median: 60%); 52% (27) patients had other comorbidities (Charlson index ranged from 6–10; median 7); 48% (25) were previous smokers; hemoglobin levels ranged from 4.9 to 16.7 g/dL (median: 12). We also evaluated 33 patients with echocardiography, and 13 (43%) of them had signs of associated pulmonary hypertension; ejection fraction ranged from 46 to 83% (median: 69%); diastolic dysfunction was present in 22 and pericardial effusion in 10 patients. At accrual, median QoL scores were of: 32% (range: 0–84%) for SF-36 (scale with 0 worst) and 66% (range: 0–100%) for SGRQ (scale with 100% worst). Treatment is showed in a table below. Median survival was of 4 months (range: 0.2–40+ months); 22 (42%) of the patients had an unusual longer survival of more than 6 months, still showing good QoL scores. Conclusions: Despite the fact that QoL is generally poor and survival is short for patients with NPL, some patients may have longer survival time and some improvement is possible with active palliative care. [Table: see text] No significant financial relationships to disclose.
AB0604 Dilute Russel Venom Time Ration Independently Predicts Mortality in Primary Antiphospholipid Syndrome
Authors: P. RJ Ames, M. Merashli, A. Ciampa, L. Iannaccone, V. Brancaccio
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Though the probability of survival at 10 years is 90.7% in the antiphospholipid syndrome (APS), eventual haemostatic of immunological predictors of mortality in primary APS (PAPS) have been poorly investigated. <h3>Objectives</h3> To identify mortality predictors in patients with PAPS. <h3>Methods</h3> Record review of all PAPS patients attending the Haemostasis Unit of the Cardarelli Hospital from 1988 to 2008. We identified 11 deceased patients (5M, 6F, age 55±9 yrs), 68 surviving thrombotic PAPS (21M, 47F, 47±14 yrs) and 29 persistent carriers of antiphospholipid antibodies (PCaPL) without thrombosis (7M, 22F,tage 50±16 yrs). The following had been tested at baseline and confirmed 6 weeks later: aPTT, DRVVT, KCT and plasma fibrinogen (FNG) by coagulation assays; IgG anticardiolipin (aCL) and von Willebrand factor (vWF) by Elisa; platelet (PLT) count on automatic analyser. <h3>Results</h3> IgG aCL (GPL) was 328±344 in deceased PAPS, 105±146 in surviving PAPS and 75±167 in PCaPL (p&lt;0.0001); aPTT ratio was 2.17±0.46 in deceased PAPS, 1.92±0.65 in surviving PAPS and 1.79±1.01 in PCaPL (p&lt;0.02); DRVVT ratio was 2.30±0.80 in deceased PAPS, 1.65±0.43 in surviving PAPS and 1.33±0.32 in PCaPL (p&lt;0.0001); plasma FNG (mg/dl) was 385±70 in deceased PAPS, 335±49 in surviving PAPS and 312±63 in PCaPL (p&lt;0.02); PLTs (10<sup>9</sup>/L) were 293±105 in deceased PAPS, 202±86 in surviving PAPS and 141±77 in PCaPL (p&lt;0.0001). KCT ratio and vWF concentration did not differ. Sex, disease duration, age at first thrombotic event, number of thrombotic events, IgG aCL titre, aPTTr, DRVVTr, FNG, vWF and platelet numbers were entered as independent variables in a stepwise Cox regression model with mortality as the dependent variable: DRVVTr was the single most powerful predictor of mortality that was 20% at 17 years. <h3>Conclusions</h3> DRVVTr is an independent predictor of mortality: efforts of future research should be aimed at measures to decrease antiphospholipid generation. <h3>References</h3> Cervera R, Serrano R, Pons-Estel GJ et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014 Jan 24 <h3>Disclosure of Interest</h3> None declared